Evidence map›Paper›PMID 32609814›Full record

Trial reportBlood2020

Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate.

Kathryn Lurain, Thomas S Uldrick, Ramya Ramaswami, Mark N Polizzotto, Priscila H Goncalves, Anaida Widell, Seth M Steinberg, Elaine S Jaffe, Stefania Pittaluga, Hao-Wei Wang and 7 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07002099 (Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07002099 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study

TypeinterventionalSponsorSecond Affiliated Hospital of Soochow UniversityRan2025 to 2028Enrolled26ConditionsLymphomasArmsSelinexor + High-dose Methotrexate + Rituximab + WBRT
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. HIV-Associated Lymphomas: Progress and New Challenges.Journal of clinical medicine · 2022
    Review
  15. HIV/AIDS Associated Lymphoma: Review.Blood and lymphatic cancer : targets and therapy · 2022
    Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Kathryn LurainHIV and AIDS Malignancy Branch.
Thomas S UldrickHIV and AIDS Malignancy Branch.
Ramya RamaswamiHIV and AIDS Malignancy Branch.
Mark N PolizzottoHIV and AIDS Malignancy Branch.
Priscila H GoncalvesHIV and AIDS Malignancy Branch.
Anaida WidellHIV and AIDS Malignancy Branch.
Seth M SteinbergBiostatistics and Data Management Section, and.
Elaine S JaffeLaboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD.
Stefania PittalugaLaboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD.
Hao-Wei WangLaboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD.
Constance M YuanLaboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD.
Mary Anne TamulaFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD.
Staci MartinPediatric Oncology Branch, CCR, NCI, NIH, Bethesda, MD; and.
Pamela L WoltersPediatric Oncology Branch, CCR, NCI, NIH, Bethesda, MD; and.
Jomy GeorgeClinical Pharmacokinetics Research Laboratory, Clinical Center Pharmacy, NIH, Bethesda, MD.
Richard F LittleHIV and AIDS Malignancy Branch.
Robert YarchoanHIV and AIDS Malignancy Branch.
AIDS United · USNational Institutes of Health · USCenter for Cancer Research · USLeidos (United States) · USNational Institutes of Health Clinical Center · US

Funding

Clinical Trials of Patients with AIDS-Related MalignanciesZIABC010888 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI YARCHOAN, ROBERT · 2009 to 2025
$20.6M
Lymphoma Disease Discovery and DefintionZIASC000550 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI JAFFE, ELAINE · 2009 to 2025
$16.9M
Pediatric Oncology Branch Behvioral Science CoreZIDBC011517 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GLOD, JOHN · 2013 to 2025
$15.6M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsAntiretroviral Therapy, Highly ActiveCentral Nervous System NeoplasmsDrug Therapy, CombinationFemaleFollow-Up StudiesHIVHIV InfectionsHumansLymphoma, Non-HodgkinMaleMethotrexateMiddle AgedPrognosisProspective StudiesMethotrexateRituximab

Identifiers

PMID32609814
PMCPMC7645985
OpenAlexW3039644143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.